Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707203 | 1.00 | UHRF1 (0.43) | UHRF1DYRK1AMEN1NPC1MAPT | |
| SCHEMBL17085656 | 1.00 | UHRF1 (0.43) | UHRF1DYRK1AMEN1NPC1MAPT | |
| SCHEMBL5256862 | 0.79 | KDM1A (0.47) | MEN1NPC1MAPTALOX15CASP1 | |
| SCHEMBL5256859 | 0.79 | KDM1A (0.47) | MEN1NPC1MAPTALOX15CASP1 | |
| SCHEMBL9798174 | 0.78 | UHRF1 (0.48) | UHRF1DYRK1AMEN1MAPTKMT2A | |
| SCHEMBL14153950 | 0.78 | UHRF1 (0.48) | UHRF1DYRK1AMEN1MAPTKMT2A | |
| SCHEMBL9798181 | 0.78 | UHRF1 (0.48) | UHRF1DYRK1AMEN1MAPTKMT2A | |
| SCHEMBL6630611 | 0.77 | — | — | |
| SCHEMBL27790862 | 0.77 | MAPT (0.62) | MEN1NPC1MAPTALOX15CASP1 | |
| SCHEMBL27898404 | 0.77 | MAPT (0.62) | MEN1NPC1MAPTALOX15CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7459563-B2 | Process for the preparation of isonicotinic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| EP-1812392-B1 | PROCESS FOR PREPARATION OF ISONICOTINIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1812392-A1 | PROCESS FOR PREPARATION OF ISONICOTINIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-20060100440-A1 | Process for the preparation of isonicotinic acid derivatives | HOFFMANN-LA ROCHE INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006048172-A1 | PROCESS FOR PREPARATION OF ISONICOTINIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | UHRF1 2502/4885DYRK1A 3656/4885MEN1 203/4885 |
| US-20060100440-A1 | Process for the preparation of isonicotinic acid derivatives | ADORA2A, ADORA2B, ADORA1 | UHRF1 2908/4885DYRK1A 3669/4885MEN1 3920/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | UHRF1 2502/4885DYRK1A 3656/4885MEN1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.